BioAdaptives, Inc. (BDPT) Research
BioAdaptives, Inc. focuses on the distribution and marketing of health and wellness products derived from natural plants and algae, catering to both human and animal needs. Their primary offerings include a range of dietary supplements. For human consumption, the company provides products such as PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, alongside the Lung Flute device. In the animal care sector, they offer Canine Regen and Equine Regen for dogs and horses, respectively. They also supply specialized base formulations, like Equine All-in-One, to professionals including trainers, horse owners, and boarding stables. Additionally, their "All-in-One" products integrate minerals, vitamins, amino acids, and other botanicals with their proprietary Regen compounds. Established in 2013, the company was initially known as APEX 8 Inc. before changing its name to BioAdaptives, Inc. in September of that year, and is headquartered in Las Vegas, Nevada.
Market snapshot
- Symbol
- BDPT
- Price
- $0.00
- Day change
- -13.92%
- Market cap
- $31.1K
- P/E ratio
- -0.03x
- 52-week range
- 0.003-0.084
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
Peer companies
Recent insider activity
- FRISSORA MARK P — J-Other (4717 shares) on 2026-06-01
- FRISSORA MARK P — J-Other (4808 shares) on 2026-05-01
- FRISSORA MARK P — J-Other (4386 shares) on 2026-04-01
- FRISSORA MARK P — J-Other (2578 shares) on 2026-03-01
- FRISSORA MARK P — J-Other (2565 shares) on 2026-02-01
Open BioAdaptives, Inc. (BDPT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.